<DOC>
	<DOCNO>NCT00454805</DOCNO>
	<brief_summary>The purpose study determine whether AZD2171 effectively improve time tumour progression add fulvestrant patient advance hormone sensitive breast cancer progress prior hormonal therapy .</brief_summary>
	<brief_title>AZD2171 Addition Fulvestrant Patients With Advanced Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Written inform consent Females histological/cytological confirmation hormone sensitive breast cancer evidence metastatic disease One evaluable lesion Prior hormonal therapy fulvestrant More one course prior systemic cytotoxic chemotherapy metastatic breast cancer Prior biologic therapy ABC include AntiVEGF agent Radiation therapy within 4 week prior provision consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
</DOC>